Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Medivir develops a new unique treatment Lipsovir cream can prevent the development of a cold sore No other drug treatment has shown this effect Avoid your next cold sore The ingredients of Lipsovir have been used safely for decades. The trick was bringing them together. aciclovir patent protection hydrocortisone formulation The Lipsovir concept is a completely new way of managing the life long infection of the cold sore virus Avoid your next cold sore Ow! IMMUNE RESPONSE Ow! Current drugs IMMUNE RESPONSE Ow! Lipsovir IMMUNE RESPONSE Drug treatment Prevents development of ulderative lesions Reduction of healing time Aciclovir1 No 10-12% Penciclovir2 No 13-15% Docosanol (Abreva)3 No 15% Valaciclovir4 No 10-11% Lipsovir5 Yes 43%6 Topical treatment Oral treatment 1 Spruance et al. Antimicrob Agents Chemother 2002 2 Spruance et al. JAMA 1997 3 Sacks et al. J Am Acad Dermatol 2001 4 Spruance et al. Antimicrob Agents Chemother 2003 5 Evans et al. Antimicrob Agents Chemother 2002 6 Combined effect of prevention of lesions and reduction of healing time Avoid your next cold sore Avoid your next cold sore Only about 1-2% of all cold sore episodes are currently treated Even so this represents an SEK 3 billion market just in the USA An effective pharmaceutical like Lipsovir is expected to expand this market Avoid your next cold sore US market labial herpes (million USD) Abreva (GSK) 50 Denavir (Novartis) 20 Zovirax cream + ointment (Biovail) 90 Other oral antivirals 20 Valtrex (GSK) 203 NB! Only 1-2% of all cold sore episodes are currently treated Total USD 383 miljon, current growth 17% (IMS) Avoid your next cold sore o Famvir (famciclovir) tablets from Novartis - Clinical trials on cold sores performed, but no regulatory approval yet - Probably no more effective than other antiviral treatments - Does not prevent development of cold sores o Transport Pharmaceuticals - developing apparatus which provides high local dosages of acyclovir via a mild electric current - appears only to shorten episode duration (phase II data) o interceptCS™ - thermal treatment of herpes episodes - approved in Canada - large, clumsy and expensive Avoid your next cold sore o Patents protect Lipsovir from generic competition until 2016 o The formulation technology (cream) is patented to 2019 (2020 in USA) o Uncommonly difficult and time-consuming for competitors to register a Lipsovir-copy o Systemic drugs – relationship exists between drug concentration in the plasma and therapeutic activity – quick and easy to do bioequivalance studies o Topical drugs – no relationship between plasma concetration and therapeutic activity – harder to prove that the copy has the same efficacy as the original o Topical drugs for cold sores – the indication has no surrogate markers – enormous clinical trials are needed to prove that the copy is not worse than the orginal o “Unusually high regulatory hurdles for topical herpes drugs” Robert W. Pollock, Lachman Consultant Services, f d Acting Deputy Director, Avoid your next cold sore FDA’s Office of Generic Drugs 1. Lipsovir phase II data showed a unique therapeutic activity 2. The results for antiviral drugs in this kind of clinical trial are predictive for efficacy in phase III 3. Discussions with FDA have evolved an attractive development programme för Lipsovir Avoid your next cold sore o All trial participants (n=380) irradiated with UV light on the lips in order to induce a cold sore episode o Two days later treatment was commenced with either Lipsovir or placebo cream o Results with antivirals in this type of clinical trial are predictive of efficacy in phase III Undvik ditt nästa munsår o In the phase II trial1 (n=380) the number of cold sores in the Lipsovir-group were 29% lower than the placebo group; the difference is statistically significant (p=0.02) o Independent studies of Spruance et al2 (n=49) o Trail participants treated with oral famciclovir + steroid cream; or oral famciclovir + placebo cream o The These number results of cold sores was 36% lower in those receiving support the phase II than in the other group (p=0.09, famciclovir + steroid cream dvs trend)trails o Preclinical data3 show that Lipsovir gives a 50% better therapeutic efficacy than acyclovir cream alone 1) Evans et al, Antimicrobial Agents & Chemotherapy 2002 2) Journal of Infectious Diseases 2000 3) Harmenberg et al, Antiviral Chemistry & Chemotherapy 2003 Avoid your next cold sore Drug Year Chief Investigator Type of study Treatment start Primary endpoint Penciclovir cream 19931994 Spruance Field study* < 1 hour after first symptom Time to healing Zovirax cream (acyclovir) 19971998 Spruance Fieldstudy* < 1 hour after first symptom Episode duration Valtrex (valaciclovir) 20002001 Spruance Fieldstudy* Directly upon first symptom 1.Episode duration 2. Number of patients who develop cold sores Lipsovir 20062007 Hull/Spruance Field study* <1 hour after first symptom Number of patients who develop cold sores * Field study: 1) Patients are given clinical trial material 2) Patients self-initiates treatment as soon as they feel the symptoms of a cold sore episode Avoid your next cold sore o A pharmaceutical with two active ingredients must usually show therapeutic superiority over o Each active ingredient on their own o Placebo o Issues which have been discussed with authorities: o Can we avoid the hydrocortisone-alone comparison? Yes o Which is the most relevant acyclovir cream for the trial? Same cream base o Is it sufficient with one pivotal trial? Yes! as Lipsovir o An agreement on the phase III programme has been reached at the End-of-Phase II meeting at the FDA o The programme has been checked with authorities in the EU Avid your next cold sore The purpose of the study is to show that Lipsovir prevents development of ulcerative lesions 1270 subjects with recurrent cold sores will be treated with one of the following Lipsovir Aciclovir cream Placebo cream Treatment is started as soon as the subjects feel the first symptoms of a cold sore (herpes). Avoid your next cold sore Clinical trials begin July 2006 Clinical trials complete Autumn 2007 Application to authorities Spring 2008 Marketing Approval End of 2008 Avoid your next cold sore A handful of experienced consultants in close collaboration with Medivir Scientific Board CRO companies in USA Clinical centres in USA and Canada CRO för Phase III trails 1 project manager 1 project assistant 6 monitors medical advisor data management statistician safety monitoring report drafting Manufacturor 1 project manager manufacturing personnel analytical chemists quality assurance Clinical trial packaging 1 project manager quality assurance programmers Undvik Avoid your next cold s o Manufacture and packaging of study drug o Applications to ethical committees and authorities o Contracting of 50 clinical centres o Designation of central laboratories for sample analysis o Drafting and printing of informational material e.g. Patient diaries and trial questionnaires (CRF) o Investigator meetings with >100 participants (training ahead of the studies) o Systems for monitoring inclusion rates Preparations July Rectruitment of > 2000 patients Avoid your next cold sore o People with 3 or more herpes episodes per year recruited to selected clinical centres o The participants are questioned on their cold sores o is the description consistent with herpes? o can the participant feel the early symptoms of a cold sore episode? o is the participant willing to live up to the trial rules? o Approved participants receive a tube with clinical trial material + a key ring container anc can return home and await their next herpes episode recruitment Patient receives their tube Waiting... It can take months symptoms 5 days treatment Clinic visits until symptom-free Treatment commences within an hour Avoid your next cold sore o An open study on 100 teenagers (12-17 years) starts in Sweden this autumn o The aim is to get approval to treat all patients over 12 years o Only recording of potential side effects o A study of 75 immunocompromised subjects starts in Russia/Ukraine this autumn o The aim is to see if the therapeutic efficacy is any different in this patient group o Both studies performed by av CRO-companies Avoid your next cold sore Medivir develops a new unique treatment Lipsovir cream can prevent the development of a cold sore No other drug treatment has shown this effect Avoid your next cold sore